The DOI matches its Crossref record.
Postlicensure Safety Surveillance for Varicella Vaccine
Abstract
CONTEXT: Since its licensure in 1995, the extensive use of varicella vaccine and close surveillance of the associated anecdotal reports of suspected adverse effects provide the opportunity to detect potential risks not observed before licensure because of the relatively small sample size and other limitations of clinical trials. OBJECTIVES: To detect potential hazards, including rare events, associated with varicella vaccine, and to assess case reports for clinical and epidemiological implications. DESIGN AND SETTING: Postlicensure case-series study of suspected vaccine adverse events reported to the US Vaccine Adverse Event Reporting System (VAERS) from March 17, 1995, through July 25, 1998. MAIN OUTCOME MEASURES: Numbers of reported adverse events, proportions, and reporting rates (reports per 100,000 doses distributed). RESULTS: VAERS received 6574 case reports of adverse events in recipients of varicella vaccine, a rate of 67.5 reports per 100,000 doses sold. Approximately 4% of reports described serious adverse events, including 14 deaths. The most frequently reported adverse events were rashes, possible vaccine failures, and injection site reactions. Misinterpretation of varicella serology after vaccination appeared to account for 17% of reports of possible vaccine failures. Among 251 patients with herpes zoster, 14 had the vaccine strain of varicella zoster virus (VZV), while 12 had the wild-type virus. None of 30 anaphylaxis cases was fatal. An immunodeficient patient with pneumonia had the vaccine strain of VZV in a lung biopsy. Pregnant women occasionally received varicella vaccine through confusion with varicella zoster immunoglobulin. Although the role of varicella vaccine remained unproven in most serious adverse event reports, there were a few positive rechallenge reports and consistency of many cases with syndromes recognized as complications of natural varicella. CONCLUSION: Most of the reported adverse events associated with varicella vaccine are minor, and serious risks appear to be rare. We could not confirm a vaccine etiology for most of the reported serious events; several will require further study to clarify whether varicella vaccine plays a role. Education is needed to ensure appropriate use of varicella serologic assays and to eliminate confusion between varicella vaccine and varicella zoster immunoglobulin. JAMA. 2000;284:1271-1279
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Prevention of Varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
(1996) · PsycEXTRA Dataset · doi:10.1037/e547262006-001 · Cited by 1,079
Heininger, U., & Seward, J. F. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69561-5 · Cited by 564
Varicella Disease After Introduction of Varicella Vaccine in the United States, 1995-2000
Seward, J. F. (2002) · JAMA · doi:10.1001/jama.287.5.606 · Cited by 557
Risk of anaphylaxis after vaccination of children and adolescents.
Bohlke, K., Davis, R. L., Marcy, S. M., Braun, M. M., DeStefano, F., Black, S. B., Mullooly, J. P., Thompson, R. S., & for the Vaccine Safety Datalink Team (2003) · PEDIATRICS · doi:10.1542/peds.112.4.815 · Cited by 320
Adverse reactions to vaccines practice parameter 2012 update
Kelso, J. M., Greenhawt, M. J., Li, J. T., Nicklas, R. A., Bernstein, D. I., Blessing-Moore, J., Cox, L., Khan, D., Lang, D. M., Oppenheimer, J., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.04.003 · Cited by 293
Metadata
- Authors
- Wise, R. P.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2000-09-13
- Volume
- 284
- Issue
- 10
- Pages
- 1271
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1989490043
- Cited by
- 213
- References
- 0
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Postlicensure Safety Surveillance for Varicella Vaccine. https://app.cochat.ai/papers/10.1001/jama.284.10.1271
- The paper
- Wise, R. P. (2000). Postlicensure Safety Surveillance for Varicella Vaccine. JAMA. https://doi.org/10.1001/jama.284.10.1271
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.